Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)
Posted inInfectious Diseases news Respiratory

Three-Month Clofazimine–Rifapentine Regimen for Drug‑Susceptible TB Failed to Improve Outcomes and Raised Safety Concerns: Lessons from Clo‑Fast (Phase 2c)

The Clo‑Fast phase 2c trial tested a 3‑month rifapentine‑clofazimine regimen versus standard 6‑month therapy for drug‑susceptible pulmonary TB. Culture conversion at 12 weeks was similar, but shorter therapy had higher grade ≥3 adverse events and worse 65‑week composite clinical outcomes, leading to early termination.
Orodispersible Ivermectin and Moxidectin–Albendazole Combinations Deliver Major Gains Against Trichuris trichiura in Children: Dose‑response, Safety, and Programmatic Implications
Posted inInfectious Diseases news Pediatrics

Orodispersible Ivermectin and Moxidectin–Albendazole Combinations Deliver Major Gains Against Trichuris trichiura in Children: Dose‑response, Safety, and Programmatic Implications

Two randomized trials from Pemba Island show orodispersible ivermectin–albendazole yields dose‑dependent high cure rates in preschool children, and moxidectin–albendazole is superior to albendazole alone in school‑aged children, both with acceptable safety.
Once-Weekly Navepegritide Raises Growth Velocity and Improves Skeletal and Functional Outcomes in Children with Achondroplasia: Results from the APPROACH Trial
Posted innews Orthopedics Pediatrics

Once-Weekly Navepegritide Raises Growth Velocity and Improves Skeletal and Functional Outcomes in Children with Achondroplasia: Results from the APPROACH Trial

The APPROACH randomized trial found once-weekly navepegritide significantly increased annualized growth velocity and produced favorable skeletal alignment and physical-function improvements in children with achondroplasia, with an acceptable short-term safety profile.
Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development
Posted inClinical Updates Infectious Diseases news Public Health

Human Monoclonal Antibody MAM01 for Malaria Prevention: Phase 1 Trial Insights and Context in Antimalarial Monoclonal Antibody Development

This review synthesizes evidence on MAM01, a monoclonal antibody targeting Plasmodium falciparum circumsporozoite protein, summarizing its first-in-human phase 1 trial demonstrating safety and protective efficacy, alongside contextual advances in monoclonal antibody-based malaria prevention.
Long-Term Clinical and Immunological Landscape Following Monkeypox Virus Infection and MVA-BN Vaccination: Insights from the Belgian MPX-COHORT and POQS-FU-PLUS Studies
Posted inClinical Updates Infectious Diseases news Public Health

Long-Term Clinical and Immunological Landscape Following Monkeypox Virus Infection and MVA-BN Vaccination: Insights from the Belgian MPX-COHORT and POQS-FU-PLUS Studies

This review synthesizes 24-month follow-up data on monkeypox virus infection and MVA-BN vaccination, detailing durable immunity post-infection, comparative antibody kinetics, and clinical sequelae, informing future vaccination strategies and patient management.
Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection
Posted inInfectious Diseases news

Shorter Is Safe: Adjusted Analyses of BALANCE Confirm Non‑Inferiority of 7‑Day Antibiotic Courses for Uncomplicated Bloodstream Infection

A post-hoc analysis of the BALANCE randomized trial shows that after accounting for treatment non-adherence using causal inference methods, 7 days of antibiotics for uncomplicated non‑Staphylococcus aureus bloodstream infection remains non‑inferior to 14 days for 90‑day mortality.